Repligen expanded its relationship with Applied Biosystems by entering into a four-year supply agreement for recombinant Protein A, which is used in the manufacture of mAbs.
“Entering this agreement is consistent with our continued commitment to be the world’s leading supplier of Protein A used in the production of monoclonal antibodies,” says Walter C. Herlihy, president and CEO of Repligen. “We anticipate continued robust growth of the monoclonal antibody market, which in turn will drive increased demand for products based on Protein A.”
According to Herlihy, there are currently 18 mAbs that have received regulatory approval with more than 150 products in various stages of clinical development. The worldwide revenues from this class of drug exceeded $20 billion in 2006 and are forecasted to exceed $30 billion in 2010, he adds.